Wright State University

1. Novartis Pharmaceuticals Corporation $313,687 7 payments
2. Roche Products Limited $178,333 256 payments
3. Regeneron Pharmaceuticals, Inc. $89,384 14 payments
4. Bayer HealthCare Pharmaceuticals Inc. $69,287 17 payments
5. AbbVie, Inc. $66,625 35 payments
6. CSL Behring $57,251 39 payments
7. TG Therapeutics, Inc. $49,751 13 payments
8. Penumbra, Inc. $37,000 55 payments
9. Biogen, Inc. $36,522 6 payments
10. Genentech, Inc. $27,500 2 payments

1. A Multicenter, Double-Blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-Term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa $286,131 5 payments
2. Observational Study of Ocrelizumab Treated Multiple Sclerosis Patients US Commitment $178,333 256 payments
3. Long Term Safety Study of PRALUENT in Patients With Heterozygous Familial Hypercholesterolemia or With Non-Familial Hypercholesterolemia at High and Very High Cardiovascular Risk and Previously Enrolled in the Neurocognitive Function Trial $89,384 14 payments
4. A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects With Acute Coronary Syndrome $57,251 39 payments
5. (ENABLE) REal world experieNce with BRIUMVI (ublituximAB-xiiy) treated patients: a Longitudinal rEgistry study $49,751 13 payments
6. Clinical Trial Pase IV (Post Marketing) (Bayer Product or TA) $45,521 1 payment
7. M14-702 $39,832 23 payments
8. Insight $37,000 55 payments
9. Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial, Assessing the Impact of Inclisiran on Major Adverse Cardiovascular Events in Participants With Established Cardiovascular Disease (Victorion-2 Prevent) $27,556 2 payments
10. Thor Ide $25,879 3 payments

1. Patient care $5,436 4 payments

Only reported on some payments, and a payment can report more than one category, so these amounts overlap.